Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.
Quinquenel, Anne
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group. [electronic resource] - American journal of hematology 07 2019 - E183-E185 p. digital
Publication Type: Clinical Trial; Letter; Multicenter Study
1096-8652
10.1002/ajh.25480 doi
Adenine--analogs & derivatives
Autoimmune Diseases--drug therapy
Disease-Free Survival
Female
Hematologic Diseases--drug therapy
Humans
Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy
Male
Piperidines
Purines--administration & dosage
Pyrazoles--administration & dosage
Pyrimidines--administration & dosage
Quinazolinones--administration & dosage
Survival Rate
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group. [electronic resource] - American journal of hematology 07 2019 - E183-E185 p. digital
Publication Type: Clinical Trial; Letter; Multicenter Study
1096-8652
10.1002/ajh.25480 doi
Adenine--analogs & derivatives
Autoimmune Diseases--drug therapy
Disease-Free Survival
Female
Hematologic Diseases--drug therapy
Humans
Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy
Male
Piperidines
Purines--administration & dosage
Pyrazoles--administration & dosage
Pyrimidines--administration & dosage
Quinazolinones--administration & dosage
Survival Rate